Arepally Lab

Gowthami Arepally, Primary Investigator

Campus mail
DUMC Box 3486

Physical address
Rm 356A Sands Building
Research Drive
Duke University Medical Center
Durham, NC 27710

Phone
Lab: 919-668-1550
Fax: 919-684-2420
Office: 919-668-3696

Education

Fellow, Hospital of the University of Pennsylvania, Philadelphia, PA

Residency, Emory University Hospitals, Atlanta, GA

Medical School, Vanderbilt University School of Medicine, Nashville, TN

Lab Members

Gowthami Arepally, MD
Associate Professor of Medicine and Pathology


Sanjay Khandelwal, PhD

Research Scientist, Division of Hematology


Grace Lee, MD

Medical Instructor, Division of Hematology


Samuel J. Francis, MD

Assistant Professor, Duke Department of Surgery


​Dayna Grant

Research Technician

Current Studies

  1. Cellular basis of heparin-induced thrombocytopenia (HIT): The main focus of our lab is to understand how the HIT immune response occurs. Dr. Khandelwal has recently identified a major role for complement activation and B-cell CD21 in the initiation of the HIT immune response. Our ongoing studies are investigating the mechanism of complement activation, role of B-cell CD21 and biomarkers of the HIT immune response. 
  2. Protamine/heparin antibodies: Our laboratory has identified a new class of heparin-dependent antibodies, anti-protamine/heparin antibodies, that develop after protamine and heparin exposure after cardiac surgery. Dr. Lee is currently investigating the biological significance of these antibodies using a monoclonal anti-protamine/heparin antibody that she has developed in the lab. 
  3. Biomarkers of arterial and venous thrombosis: Dr. Francis in the lab is investigating novel biomarkers for early detection of arterial and venous thrombosis in patients presenting to the emergency room.

Featured Publications

Khandelwal, S., G. M. Lee, C. G. Hester, M. Poncz, S. E. McKenzie, B. S. Sachais, L. Rauova, G. Kelsoe, D. B. Cines, M. Frank and G. M. Arepally (2016). "The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21)." Blood 128(14): 1789-1799.

Lee, G. M., I. J. Welsby, B. Phillips-Bute, T. L. Ortel and G. M. Arepally (2013). "High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass." Blood 121(15): 2828-2835.